Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.84) by 5.95 percent. This is a 141.58 percent decrease over earnings of $1.90 per share from the same period last year. The company reported quarterly sales of $6.229 million which beat the analyst consensus estimate of $5.880 million by 5.94 percent. This is a 96.07 percent decrease over sales of $158.569 million the same period last year.